Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study

Fig. 1

Expression of Her2. a pTNM stage I gastric adenocarcinoma; b + from pTNM stage III gastric adenocarcinoma; c ++ from pTNM stage II gastric adenocarcinoma; d +++ from pTNM stage II gastric adenocarcinoma. The positivity degree of Her2 expression follows the National Comprehensive Cancer Network guidelines (https://www.nccn.org): − means “no reactivity or membranous reactivity in < 10% of cancer cells”; + means “faint or barely perceptible membranous reactivity in ≥ 10% of cancer cells; cells are reactive only in part of their membrane”; ++ means “weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of cancer cells”; +++ means “strong complete, basolateral, or lateral membranous reactivity in ≥ 10% of cancer cells”. Her2, human epidermal growth factor receptor 2

Back to article page